Skip to main content

Table 1 Original Measles Vaccination Balance Sheet.

From: Knowledge synthesis of benefits and adverse effects of measles vaccination: the Lasbela balance sheet

(1) Condition (2) Measles complication rate among unvaccinateda (3) Vaccine adverse event rate (4) Risk Difference (5) Number Needed to Treat (NNT) (6) Expected Gain per thousande
Diarrhoea in highly developed countries 0.08 0.0357 0.0443 23 30
Diarrhoea - WHO South Asia subregion adjusted 0.41 0.0045 0.4055 3 277
Bronchopneumonia in highly developed countries 0.01-0.06 0 0.01 100 7
Bronchopneumonia - WHO South Asia subregion adjusted 0.089-0.53 0 0.089 11 61
Blindness (Africa) 0.04 b 0 0.04 25 27
Otitis media 0.07-0.09 0.0333 0.0367 27 25
Death in highly developed countries 0.001-0.003 0.0002 0.0008 1,189 0.6
Death - WHO South Asia subregion data 0.0228 0.0002 0.0208 50 14
Death in developing world (by some estimates) 15% 0.0002 0.1498 7 102
Convulsions 0.006-0.007c 0.0022 0.0038 266 3
Post-infectious encephalitis 0.001-0.0005 0.0004 0.0006 1,591 0.4
Subacute sclerosing panencephalitis (SSPE) 0.00001 0 0.00001 100,000 7/million
Anaphylaxis 0d 1-3.5 per million -0.000001 -1,000,000 -7/ten million
  1. a Except where noted all figures in this column taken from Strebel et al [44]. b [45]. c [51]. d [33].
  2. e Gain = RDx(PRIxVER), where RD = risk difference, PRI = proportion requiring intervention (0.76), VER = vaccine efficacy rate (0.90).
  3. The bold-font rows show the conditions for which the data are most applicable to the South Asia region or, at least, developing country conditions - diarrhoea, pneumonia, blindness and death.